New approaches to Diabetes management could transform healthcare in Saudi Arabia
Saudi Arabia has a high prevalence (17.6%) of type 2 diabetes.
26 February 2017
- Boehringer Ingelheim sponsors the fourth International Conference of Endocrinology and diabetes conference in Riyadh
- Saudi Arabia has a high prevalence (17.6%) of type 2 diabetes. It is forecasted that the incidence of the disease will increase to 45.36% in 2030
Kingdom Saudi Arabia – Riyadh – The Saudi Society of Endocrinology and Metabolism (SSEM) recently organized Fourth International Conference of Endocrinology and Diabetes Conference (ICED), which was held in Al Faisaliah Hotel, Riyadh.
Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, participated as a co-sponsor in the event, which was attended by leading endocrinologists, diabetologists, cardiologists as well as pediatricians.
The ICED aims to provide an update and comprehensive review across the fields of endocrinology, diabetes and metabolism for both adults and pediatrics. Industry professionals came together to find new ways of changing the paradigm around diabetes management, with an objective of driving a better quality of healthcare delivery.
According to the International Diabetes Federation, the rate of type 2 diabetes in the Middle East North Africa (MENA) region will rise by 96.2% by 2035.  There were 3.4 million cases of diabetes in Saudi Arabia in 2015 alone. Diabetes is also the second highest cause of death after road injuries in the Kingdom.
Dr. Atallah Al-Ruhaily, President of Saudi Society of Endocrinology and Metabolism; Consultant Endocrinology at the King Abdulaziz Univers Continue reading